vs

Side-by-side financial comparison of American Homes 4 Rent (AMH) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

American Homes 4 Rent is the larger business by last-quarter revenue ($455.0M vs $267.3M, roughly 1.7× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 4.2%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 3.6%).

American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

AMH vs ASND — Head-to-Head

Bigger by revenue
AMH
AMH
1.7× larger
AMH
$455.0M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+38.1% gap
ASND
42.3%
4.2%
AMH
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
3.6%
AMH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMH
AMH
ASND
ASND
Revenue
$455.0M
$267.3M
Net Profit
$144.3M
Gross Margin
90.5%
Operating Margin
Net Margin
31.7%
Revenue YoY
4.2%
42.3%
Net Profit YoY
0.3%
EPS (diluted)
$0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMH
AMH
ASND
ASND
Q4 25
$455.0M
$267.3M
Q3 25
$478.5M
$230.7M
Q2 25
$457.5M
$170.7M
Q1 25
$459.3M
$109.0M
Q4 24
$436.6M
$187.8M
Q3 24
$445.1M
$62.5M
Q2 24
$423.5M
$38.9M
Q1 24
$423.6M
$103.6M
Net Profit
AMH
AMH
ASND
ASND
Q4 25
$144.3M
Q3 25
$116.8M
$-65.9M
Q2 25
$123.6M
$-42.0M
Q1 25
$128.7M
$-102.2M
Q4 24
$143.9M
Q3 24
$87.6M
$-107.1M
Q2 24
$108.5M
$-118.1M
Q1 24
$128.1M
$-141.5M
Gross Margin
AMH
AMH
ASND
ASND
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Q1 24
92.1%
Operating Margin
AMH
AMH
ASND
ASND
Q4 25
Q3 25
5.1%
Q2 25
-33.5%
Q1 25
-103.2%
Q4 24
Q3 24
-167.3%
Q2 24
-370.2%
Q1 24
-51.2%
Net Margin
AMH
AMH
ASND
ASND
Q4 25
31.7%
Q3 25
24.4%
-28.5%
Q2 25
27.0%
-24.6%
Q1 25
28.0%
-93.7%
Q4 24
33.0%
Q3 24
19.7%
-171.5%
Q2 24
25.6%
-303.9%
Q1 24
30.2%
-136.6%
EPS (diluted)
AMH
AMH
ASND
ASND
Q4 25
$0.33
Q3 25
$0.27
Q2 25
$0.28
Q1 25
$0.30
Q4 24
$0.33
Q3 24
$0.20
Q2 24
$0.25
Q1 24
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMH
AMH
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$108.5M
$665.3M
Total DebtLower is stronger
$5.1B
Stockholders' EquityBook value
$7.0B
$-175.8M
Total Assets
$13.2B
$1.4B
Debt / EquityLower = less leverage
0.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMH
AMH
ASND
ASND
Q4 25
$108.5M
$665.3M
Q3 25
$45.6M
$582.2M
Q2 25
$323.3M
$533.6M
Q1 25
$69.7M
$559.4M
Q4 24
$199.4M
$604.3M
Q3 24
$162.5M
$675.6M
Q2 24
$718.4M
$279.4M
Q1 24
$124.8M
$345.9M
Total Debt
AMH
AMH
ASND
ASND
Q4 25
$5.1B
Q3 25
$4.8B
Q2 25
$5.2B
Q1 25
$4.9B
Q4 24
$5.0B
Q3 24
$4.5B
Q2 24
$5.0B
Q1 24
$4.5B
Stockholders' Equity
AMH
AMH
ASND
ASND
Q4 25
$7.0B
$-175.8M
Q3 25
$7.2B
$-188.0M
Q2 25
$7.2B
$-202.6M
Q1 25
$7.2B
$-205.0M
Q4 24
$7.2B
$-114.2M
Q3 24
$7.0B
$-105.1M
Q2 24
$7.0B
$-346.8M
Q1 24
$7.0B
$-257.2M
Total Assets
AMH
AMH
ASND
ASND
Q4 25
$13.2B
$1.4B
Q3 25
$13.3B
$1.2B
Q2 25
$13.6B
$1.2B
Q1 25
$13.3B
$1.1B
Q4 24
$13.4B
$1.3B
Q3 24
$12.8B
$1.2B
Q2 24
$13.3B
$819.0M
Q1 24
$12.8B
$866.7M
Debt / Equity
AMH
AMH
ASND
ASND
Q4 25
0.72×
Q3 25
0.68×
Q2 25
0.72×
Q1 25
0.69×
Q4 24
0.70×
Q3 24
0.64×
Q2 24
0.71×
Q1 24
0.64×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMH
AMH
ASND
ASND
Operating Cash FlowLast quarter
$864.3M
$58.2M
Free Cash FlowOCF − Capex
$823.7M
FCF MarginFCF / Revenue
181.0%
Capex IntensityCapex / Revenue
8.9%
Cash ConversionOCF / Net Profit
5.99×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMH
AMH
ASND
ASND
Q4 25
$864.3M
$58.2M
Q3 25
$223.3M
Q2 25
$271.9M
Q1 25
$223.4M
$-15.5M
Q4 24
$811.5M
$-330.7M
Q3 24
$233.6M
Q2 24
$274.0M
Q1 24
$201.8M
$-109.7M
Free Cash Flow
AMH
AMH
ASND
ASND
Q4 25
$823.7M
Q3 25
$214.5M
Q2 25
$257.7M
Q1 25
$215.9M
Q4 24
$777.5M
Q3 24
$225.3M
Q2 24
$263.3M
Q1 24
$191.0M
FCF Margin
AMH
AMH
ASND
ASND
Q4 25
181.0%
Q3 25
44.8%
Q2 25
56.3%
Q1 25
47.0%
Q4 24
178.1%
Q3 24
50.6%
Q2 24
62.2%
Q1 24
45.1%
Capex Intensity
AMH
AMH
ASND
ASND
Q4 25
8.9%
Q3 25
1.8%
Q2 25
3.1%
Q1 25
1.6%
Q4 24
7.8%
Q3 24
1.9%
Q2 24
2.5%
Q1 24
2.6%
Cash Conversion
AMH
AMH
ASND
ASND
Q4 25
5.99×
Q3 25
1.91×
Q2 25
2.20×
Q1 25
1.74×
Q4 24
5.64×
Q3 24
2.67×
Q2 24
2.52×
Q1 24
1.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons